Article

Multiple sclerosis (MS) is a complex disease of the central nervous system (CNS),
characterized by CNS-restricted inflammation with subsequent demyelination and
neurodegeneration. Current disease-modifying therapies efficiently reduce relapse
rate and new lesions appearance, but still fail to impact the progressive course
of the disease. There is a great need for the avenue of new therapies aimed at
promoting myelin repair or reducing neurodegeneration that should result in the
prevention of neurological disability in this chronic disease. This review will
focus on the potentials and limitations of biotherapies that are currently
developed for the promotion of CNS repair in MS, either monoclonal antibodies
targeting axonal growth and remyelination, or cell therapies aimed at replacing
the depleted myelinating cells within the CNS. As other researches aimed at
promoting neuroprotection or remyelination are following a classical
pharmacological approach, they will not be described in this review, which will
focus on antibody-based therapies and cell therapies.
CI - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
SEP - Thérapies cellulaires
- Anticorps monoclonaux

Langue : ANGLAIS